是时候解除IL-23抑制剂用于轴向银屑病关节炎的禁令
本文为个人观点文章,指出IL-23抑制剂在轴向脊柱关节炎试验失败后被专家小组外推至轴向银屑病关节炎并推荐禁用,但临床试验事后分析显示乌司奴单抗、古塞奇尤单抗和瑞莎珠单抗治疗轴向银屑病关节炎可见临床改善,真实世界证据亦显示脊柱疼痛及影像学炎症改善,作者建议重新考虑该禁令并特别关注非HLA-B27相关表型。
要点
- IL-23抑制剂在轴向脊柱关节炎试验失败后被外推禁用于轴向银屑病关节炎。
- 乌司奴单抗、古塞奇尤单抗和瑞莎珠单抗的事后分析显示轴向银屑病关节炎临床改善。
- 真实世界证据显示脊柱疼痛、相关结局指标及影像学炎症明显改善。
核心结论
- 轴向脊柱关节炎与轴向银屑病关节炎在临床、微解剖和免疫学上存在差异,提示对IL-23通路的依赖不同,应重新考虑IL-23抑制剂禁令,尤其在不与HLA-B27相关的表型中。
研究设计与样本
- 本文为Personal View个人观点文章,基于临床试验事后分析和真实世界证据进行论述。
主要发现
- 乌司奴单抗、古塞奇尤单抗和瑞莎珠单抗的临床试验事后分析显示轴向银屑病关节炎患者临床改善。
- 真实世界证据显示脊柱疼痛、相关结局指标及影像学检测的炎症获得实质性改善。
- 尽管试验阴性,IL-23抑制在强直性脊柱炎中与C反应蛋白下降及MRI评分部分改善相关。
- 轴向脊柱关节炎中生物制剂治疗反应不足与MRI确定的骨髓水肿缺失相关,而司库奇尤单抗的反应独立于骨髓水肿。
临床怎么用
- 对轴向银屑病关节炎患者,尤其非HLA-B27相关表型,可考虑重新评估IL-23抑制剂的治疗选择。
局限性
- 本文为个人观点文章,证据主要来自事后分析和真实世界证据,非前瞻性对照研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The disappointment stemming from IL-23 inhibition failure in axial spondyloarthritis has resulted in expert panels extrapolating these results to axial psoriatic arthritis, with recommendations against the use of IL-23 inhibitors in this setting. However, post-hoc analyses of clinical trials show clinical improvements in axial psoriatic arthritis following treatment with ustekinumab, guselkumab, and risankizumab. A growing body of real-world evidence also shows substantial amelioration of spinal pain, related outcome measures, and imaging-detected inflammation. Despite negative trials, IL-23 inhibition was associated with C-reactive protein reductions and some improvement in MRI scores in ankylosing spondylitis, indicating some modicum of potential benefit. Furthermore, inadequate response to biological therapies in axial spondyloarthritis was associated with absence of MRI-determined bone marrow oedema, whereas responses to secukinumab in axial spondyloarthritis were independent of bone marrow oedema, pointing to divergent pathophysiological processes. The growing recognition of clinical, microanatomical, and immunological differences between axial spondyloarthritis and axial psoriatic arthritis suggests differential IL-23 pathway dependence. This Personal View aims to provide a deeper examination of these distinctions as a basis to propose reconsidering the current moratorium on IL-23 inhibitors-particularly in phenotypes not linked to HLA-B27-and to potentially expand therapeutic options.
引用
- Tonutti A, Abacar K, Macleod T, et al. Time to lift the moratorium on IL-23 inhibitors for axial psoriatic arthritis. Lancet Rheumatol. 2025. PMID: 41319674. doi:10.1016/S2665-9913(25)00287-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。